Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High dose daily interferon-alpha induction and secondary adjunction of ribavirin in treatment-naive patients with chronic hepatitis C. A multicentric, randomised, controlled trial.
Wartelle-Bladou C, Arpurt JP, Renou C, Pariente A, Pillon D, Nalet B, Picon M, Glibert A, Chousterman M, Grasset D, Morin T, Bernard P, Fischer D, Ramdani M, Lagier E, Rotily M; Viral Hepatitis Group of the ANGH. Wartelle-Bladou C, et al. Gastroenterol Clin Biol. 2006 Apr;30(4):525-32. doi: 10.1016/s0399-8320(06)73221-3. Gastroenterol Clin Biol. 2006. PMID: 16733374 Free article. Clinical Trial.
Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients.
Bourliere M, Penaranda G, Ouzan D, Renou C, Botta-Fridlund D, Tran A, Rosenthal E, Wartelle-Bladou C, Delasalle P, Oules V, Portal I, Castellani P, Lecomte L, Rosenthal-Allieri MA, Halfon P. Bourliere M, et al. Aliment Pharmacol Ther. 2008 Aug 15;28(4):458-67. doi: 10.1111/j.1365-2036.2008.03742.x. Epub 2008 May 22. Aliment Pharmacol Ther. 2008. PMID: 18498446
Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy.
Thabut D, Bureau C, Layese R, Bourcier V, Hammouche M, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Goria O, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle-Bladou C, Dao T, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Hillaire S, Di Martino V, Sutton A, Audureau E, Roudot-Thoraval F, Nahon P; ANRS CO12 CirVir group. Thabut D, et al. Among authors: wartelle bladou c. Gastroenterology. 2019 Mar;156(4):997-1009.e5. doi: 10.1053/j.gastro.2018.11.053. Epub 2019 Feb 13. Gastroenterology. 2019. PMID: 30768988
[Management of hepatitis C among drug user patients].
Moussalli J, Melin P, Wartelle-Bladou C, Lang JP. Moussalli J, et al. Gastroenterol Clin Biol. 2007 Aug-Sep;31(8-9 Pt 3):4S51-5. Gastroenterol Clin Biol. 2007. PMID: 17965636 Free article. Review. French.
Chronic hepatitis C: treatments of the future.
Bourlière M, Khaloun A, Wartelle-Bladou C, Oules V, Portal I, Benali S, Adhoute X, Castellani P. Bourlière M, et al. Clin Res Hepatol Gastroenterol. 2011 Dec;35 Suppl 2:S84-95. doi: 10.1016/S2210-7401(11)70013-4. Clin Res Hepatol Gastroenterol. 2011. PMID: 22248700
Future treatment of patients with HCV cirrhosis.
Bourlière M, Khaloun A, Wartelle-Bladou C, Oules V, Portal I, Benali S, Adhoute X, Castellani P. Bourlière M, et al. Liver Int. 2012 Feb;32 Suppl 1:113-9. doi: 10.1111/j.1478-3231.2011.02702.x. Liver Int. 2012. PMID: 22212581 Review.
22 results